Matthew Wongchenko
Overview
Explore the profile of Matthew Wongchenko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K -Mutant Melanoma
Pires da Silva I, Wang K, Wilmott J, Holst J, Carlino M, Park J, et al.
Clin Cancer Res
. 2019 Jan;
25(4):1272-1279.
PMID: 30630828
Purpose: V600E and V600K melanomas have distinct clinicopathologic features, and V600K appear to be less responsive to ±. We investigated mechanisms for this and explored whether genotype affects response to...
12.
Wang K, Menzies A, Silva I, Wilmott J, Yan Y, Wongchenko M, et al.
Bioinformatics
. 2018 Sep;
35(8):1350-1357.
PMID: 30215668
Motivation: Gene annotation and pathway databases such as Gene Ontology and Kyoto Encyclopaedia of Genes and Genomes are important tools in Gene-Set Test (GST) that describe gene biological functions and...
13.
Wagle M, Kirouac D, Klijn C, Liu B, Mahajan S, Junttila M, et al.
NPJ Precis Oncol
. 2018 Jun;
2(1):7.
PMID: 29872725
- and -mutant tumors are often dependent on MAPK signaling for proliferation and survival and thus sensitive to MAPK pathway inhibitors. However, clinical studies have shown that MEK inhibitors are...
14.
McQuade J, Daniel C, Hess K, Mak C, Wang D, Rai R, et al.
Lancet Oncol
. 2018 Feb;
19(3):310-322.
PMID: 29449192
Background: Obesity has been linked to increased mortality in several cancer types; however, the relation between obesity and survival outcomes in metastatic melanoma is unknown. The aim of this study...
15.
Guler G, Tindell C, Pitti R, Wilson C, Nichols K, KaiWai Cheung T, et al.
Cancer Cell
. 2017 Aug;
32(2):221-237.e13.
PMID: 28781121
Maintenance of phenotypic heterogeneity within cell populations is an evolutionarily conserved mechanism that underlies population survival upon stressful exposures. We show that the genomes of a cancer cell subpopulation that...
16.
Ascierto P, McArthur G, Dreno B, Atkinson V, Liszkay G, Di Giacomo A, et al.
Lancet Oncol
. 2016 Aug;
17(9):1248-60.
PMID: 27480103
Background: The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAF(V600)-mutant advanced melanoma, as previously reported in the coBRIM study....
17.
Vinogradova M, Gehling V, Gustafson A, Arora S, Tindell C, Wilson C, et al.
Nat Chem Biol
. 2016 May;
12(7):531-8.
PMID: 27214401
The KDM5 family of histone demethylases catalyzes the demethylation of histone H3 on lysine 4 (H3K4) and is required for the survival of drug-tolerant persister cancer cells (DTPs). Here we...
18.
Yu N, Kakunda M, Pham V, Lill J, Du P, Wongchenko M, et al.
Mol Cell Biol
. 2015 Feb;
35(8):1390-400.
PMID: 25645927
The Wnt/β-catenin pathway causes accumulation of β-catenin in the cytoplasm and its subsequent translocation into the nucleus to initiate the transcription of the target genes. Without Wnt stimulation, β-catenin forms...
19.
Edgar K, Crocker L, Cheng E, Wagle M, Wongchenko M, Yan Y, et al.
Genes Cancer
. 2014 Jul;
5(3-4):113-26.
PMID: 25053989
Phosphoinositide-3 kinase (PI3K) signaling pathway alterations occur broadly in cancer and PI3K is a promising therapeutic target. Here, we investigated acquired resistance to GDC-0941, a PI3K inhibitor in clinical trials....
20.
Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodriguez O, et al.
Clin Cancer Res
. 2013 Oct;
19(24):6976-86.
PMID: 24141624
Purpose: The oncogenic PI3K/Akt/mTOR pathway is an attractive therapeutic target in cancer. However, it is unknown whether the pathway blockade required for tumor growth inhibition is clinically achievable. Therefore, we...